Biomarin Pharmaceutical (BMRN) Total Non-Current Liabilities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $2.2 billion for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 81.67% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 81.67% YoY) and the FY2025 annual result came in at $1.4 billion, up 12.82% from the prior year.
• Total Non-Current Liabilities advanced to $2.2 billion in Q1 2026, from $1.4 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.2 billion in Q1 2026 and troughed at $1.2 billion in Q4 2024.
• A 5-year average of $1.6 billion and a median of $1.7 billion in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 32.09% — and 2026, when it soared 81.67%.
• Tracing BMRN's Total Non-Current Liabilities over 5 years: stood at $1.7 billion in 2022, then grew by 5.87% to $1.8 billion in 2023, then tumbled by 32.09% to $1.2 billion in 2024, then climbed by 12.82% to $1.4 billion in 2025, then soared by 63.95% to $2.2 billion in 2026.
• Business Quant data shows BMRN's Total Non-Current Liabilities at $2.2 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.